Bright Minds Biosciences Stock Piotroski F Score
| DRUG Stock | USD 32.38 0.29 0.89% |
Bright | Piotroski F Score |
At this time, it appears that Bright Minds' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | No Change |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
Bright Minds Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Bright Minds is to make sure Bright is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Bright Minds' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Bright Minds' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 567.5 K | 323 K |
|
| |||||
| Total Assets | 8.8 M | 7.9 M |
|
| |||||
| Total Current Assets | 8.7 M | 7.8 M |
|
|
Bright Minds Biosciences F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Bright Minds' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Bright Minds in a much-optimized way.
| 0.41 | -0.67 | 0.56 | -0.49 | -0.49 | 0.8 | ||
| 0.41 | -0.76 | -0.51 | -0.99 | -0.99 | 0.82 | ||
| -0.67 | -0.76 | 0.05 | 0.77 | 0.77 | -0.94 | ||
| 0.56 | -0.51 | 0.05 | 0.44 | 0.44 | 0.03 | ||
| -0.49 | -0.99 | 0.77 | 0.44 | 1.0 | -0.85 | ||
| -0.49 | -0.99 | 0.77 | 0.44 | 1.0 | -0.85 | ||
| 0.8 | 0.82 | -0.94 | 0.03 | -0.85 | -0.85 |
Click cells to compare fundamentals
About Bright Minds Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Bright Minds ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bright Minds' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bright Minds' managers, analysts, and investors.Environmental | Governance | Social |
About Bright Minds Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bright Minds Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bright Minds using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bright Minds Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Bright Minds Altman Z Score, Bright Minds Correlation, Bright Minds Valuation, as well as analyze Bright Minds Alpha and Beta and Bright Minds Hype Analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.